SCHEMBL3706546

SCHEMBL3706546

C=CCc1cc(C(C)(C)C)ccc1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 4/20 0.59
GABRB2 P47870 4/20 0.59
CYP2D6 P10635 3/20 0.57
ALDH1A1 P00352 4/20 0.52
HPGD P15428 3/20 0.52
ALOX15 P16050 1/20 0.52
HSD17B10 Q99714 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
POLB P06746 2/20 0.51
KLF10 Q13118 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP2C19 P33261 1/20 0.48
MAPT P10636 4/20 0.47
MEN1 O00255 3/20 0.47
GAA P10253 3/20 0.47
KMT2A Q03164 3/20 0.47
CNR1 P21554 2/20 0.47
CNR2 P34972 2/20 0.47
ALOX5 P09917 1/20 0.47
GABRB1 P18505 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29364812 0.89 KLF10 (0.62) GABRA1GABRB2CYP2D6ALDH1A1HPGD
SCHEMBL122346 0.89 KLF10 (0.62) GABRA1GABRB2CYP2D6ALDH1A1HPGD
SCHEMBL29395400 0.89 KLF10 (0.62) GABRA1GABRB2CYP2D6ALDH1A1HPGD
SCHEMBL30003149 0.88 KLF10 (0.61) GABRA1GABRB2CYP2D6ALDH1A1HPGD
SCHEMBL13609960 0.88 KLF10 (0.61) GABRA1GABRB2CYP2D6ALDH1A1HPGD
SCHEMBL27179060 0.86 GABRA1 (0.56) GABRA1GABRB2CYP2D6ALDH1A1HPGD
SCHEMBL1980255 0.86 ALDH1A1 (0.52) GABRA1GABRB2CYP2D6ALDH1A1HPGD
SCHEMBL28424894 0.85 GABRA1 (0.54) GABRA1GABRB2CYP2D6ALDH1A1HPGD
SCHEMBL20684728 0.85 GABRA1 (0.54) GABRA1GABRB2CYP2D6ALDH1A1HPGD
SCHEMBL8674767 0.83 KLF10 (0.56) GABRA1GABRB2CYP2D6ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9115263-B2 Composite materials and method for making high-performance carbon nanotube reinforced polymer composites FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2015-08-25 US claimed
US-20130264521-A1 Composite Materials and Method for Making High-Performance Carbon Nanotube Reinforced Polymer Composites FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2013-10-10 US claimed
US-20120123061-A1 Composite Materials and Method for Making High-Performance Carbon Nanotube Reinforced Polymer Composites FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-05-17 US claimed
EP-1053744-B1 Substituted phenols as fragrance, flavor and antimicrobial compounds TAKASAGO PERFUMERY CO LTD (JP) 2005-04-27 EP claimed
EP-1053744-A2 Substituted phenols as fragrance, flavor and antimicrobial compounds Takasago International Corporation (JP) 2000-11-22 EP claimed
US-6110888-A PHENOL SUBSTITUTED WITH ONE OF: PROPYL OR PROPENYL; ONE OF: HYDROGEN OR ALKYL; AND ONE TO THREE C3-C5 ALKYL GROUPS; FRAGRANCE AND ANTIMICROBIAL PROPERTIES; USE SUCH AS IN MOUTHWASHES TAKASAGO INTERNATIONAL CORPORATION (JP) 2000-08-29 US claimed
EP-4698582-A1 CURABLE ORGANOSILOXANE-MODIFIED REACTION RESINS Wacker Chemie AG (DE) 2026-02-25 EP disclosed
US-20250145562-A1 VISIBLE LIGHT ABSORBERS FOR OPHTHALMIC DEVICES JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2025-05-08 US disclosed
WO-2025093198-A1 VISIBLE LIGHT ABSORBERS FOR OPHTHALMIC DEVICES BAUSCH + LOMB IRELAND LIMITED (IE) 2025-05-08 WO disclosed
WO-2025031588-A1 CURABLE ORGANOSILOXANE-MODIFIED REACTION RESINS WACKER CHEMIE AG (DE) 2025-02-13 WO disclosed
WO-2024217692-A1 CURABLE ORGANOSILOXANE-MODIFIED REACTION RESINS WACKER CHEMIE AG (DE) 2024-10-24 WO disclosed
WO-2024213237-A1 CURABLE ORGANOSILOXANE-MODIFIED REACTION RESINS WACKER CHEMIE AG (DE) 2024-10-17 WO disclosed
US-9115263-B2 Composite materials and method for making high-performance carbon nanotube reinforced polymer composites FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2015-08-25 US disclosed
US-20080300298-A1 Honokiol Derivates For the Treatment of Proliferative Disorders NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-12-04 US disclosed
EP-1053744-B1 Substituted phenols as fragrance, flavor and antimicrobial compounds TAKASAGO PERFUMERY CO LTD (JP) 2005-04-27 EP disclosed
US-6306979-B1 Derivatized carbon monoxide copolymers BASF AKTIENGESELLSCHAFT (DE) 2001-10-23 US disclosed
US-6284868-B1 AT LEAST ONE 1-ALKENE THAT IS AN ARYL DERIVATIVE SUBSTITUTED WITH AT LEAST ONE TERMINAL ALLYL AND/OR HOMOALLYL MOIETY AND CONTAINING ONE OR MORE POLAR GROUPS; GROUP VIII METAL COMPLEX CATALYST BASF AKTIENGESELLSCHAFT (DE) 2001-09-04 US disclosed
EP-1053744-A2 Substituted phenols as fragrance, flavor and antimicrobial compounds Takasago International Corporation (JP) 2000-11-22 EP disclosed
US-6110888-A PHENOL SUBSTITUTED WITH ONE OF: PROPYL OR PROPENYL; ONE OF: HYDROGEN OR ALKYL; AND ONE TO THREE C3-C5 ALKYL GROUPS; FRAGRANCE AND ANTIMICROBIAL PROPERTIES; USE SUCH AS IN MOUTHWASHES TAKASAGO INTERNATIONAL CORPORATION (JP) 2000-08-29 US disclosed
WO-1999058607-A1 POLYMER MIXTURES CONTAINING CARBON MONOXIDE/α-OLEFIN COPOLYMERS AND COPOLYMERS MADE OF VINYL AROMATIC COMPOUNDS AND VINYL CYANIDES BASF AKTIENGESELLSCHAFT (DE) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145562-A1 VISIBLE LIGHT ABSORBERS FOR OPHTHALMIC DEVICES CRY1, NFXL1, ZYX GABRA1 2575/4885GABRB2 3259/4885CYP2D6 332/4885
US-20080300298-A1 Honokiol Derivates For the Treatment of Proliferative Disorders CCNK, CDK3, CCNO GABRA1 4042/4885GABRB2 4180/4885CYP2D6 3909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.